Intelligence · Clinical Pipeline
RIGEL PHARMACEUTICALS Pipeline
All ClinicalTrials.gov programs at RIGEL PHARMACEUTICALS — phase, modality, and trial IDs.
- Programs
- 4
Quick answer
RIGEL PHARMACEUTICALS has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Fostamatinib
RIGEL PHARMACEUTICALS INC
Chronic Graft Versus Host Disease
1 trial -
Fostamatinib 100 mg bid and Paclitaxel
RIGEL PHARMACEUTICALS INC
Ovarian Cancer
1 trial -
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
RIGEL PHARMACEUTICALS INC
Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
Olutasidenib Investigational Agent Administration
RIGEL PHARMACEUTICALS INC
Acute Myeloid Leukemia
1 trial
Frequently asked questions
How many pipeline programs does RIGEL PHARMACEUTICALS have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs